Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3880)

(1) APPOINTMENT OF CHIEF FINANCIAL OFFICER; (2) RESIGNATION OF JOINT COMPANY SECRETARIES, CHANGE OF AUTHORISED REPRESENTATIVES, PROCESS AGENT AND SECRETARY TO THE BOARD, AND APPOINTMENT OF COMPANY SECRETARY; AND (3) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the "**Board**") of directors (the "**Director(s)**") of Medtide Inc. (the "**Company**" together with its subsidiaries, the "**Group**") hereby announces that with effect from July 31, 2026:

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board hereby announces that Ms. Ding Lijun ("**Ms. Ding**") has been appointed as the Chief Financial Officer with effect from July 31, 2026. Ms. Ding will be primarily responsible for the overall financial strategy and management of the Group.

The biographical details of Ms. Ding are as follows:

Ms. Ding, aged 50, has had 27 years of management experience in the fields of finance, business development and operations. Prior to joining the Group, Ms. Ding was a chief financial officer of Inventronics (Hangzhou), Inc. from February 2025 to July 2026. Ms. Ding has also previously worked at several listed companies, including serving as a finance vice president at Innovent Biologics, Inc. (a company listed on the Stock Exchange, stock code: 1801) from 2022 to 2024, and a chief financial officer and secretary to the board of directors of Anhui Korrun Co., Ltd. (安徽開潤股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 300577.SZ) from 2013 to 2020.

Ms. Ding obtained a Bachelor's degree in International Accounting from Liaoning Petrochemical University in July 1998 and a Master's degree in Accounting from Pace University in July 2005.

Ms. Ding did not hold any directorships in any listed public companies in Hong Kong or overseas in the last three years and she had no relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company.

The Company believes the appointment of chief financial officer aligns with the Company's long-term and international development strategy.

RESIGNATION OF JOINT COMPANY SECRETARIES, CHANGE OF AUTHORISED REPRESENTATIVES, PROCESS AGENT AND SECRETARY TO THE BOARD, AND APPOINTMENT OF COMPANY SECRETARY

The Board further announces that with effect from July 31, 2026:

(1) Mr. Ng Tung Ching Raphael ("**Mr. Ng**") has tendered his resignation as (i) the joint company secretary of the Company ("**Joint Company Secretary(ies)**"); (ii) an authorised representative of the Company (the "**Authorised Representative**") for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"); and (iii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong as required under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**"); and

(2) Ms. Li Lingmei ("**Ms. Li**") has tendered her resignation as (i) secretary to the Board; (ii) the Joint Company Secretary; and (iii) the Authorised Representative. Ms. Li will continue to act as the executive Director of the Company.

Each of Mr. Ng and Ms. Li has confirmed that there are no matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to their respective resignations.

The Board is pleased to announce that, with effect from July 31, 2026, following the resignation of Ms. Li as the secretary to the Board, Ms. Ding has been appointed as the secretary to the Board.

The Board further announces that, following the resignation of Ms. Li as the Authorised Representative, with effect from July 31, 2026, Dr. Xu Qi ("**Dr. Xu**"), chairwoman of the Board, executive Director and the Chief Executive Officer of the Company has been appointed as the Authorised Representative.

The Board further announces that, following the resignations of Mr. Ng and Ms. Li as Joint Company Secretaries, Mr. Chan Ching ("**Mr. Chan**") has been appointed as the company secretary of the Company (the "**Company Secretary**"), the Authorised Representative and the Process Agent with effective from July 31, 2026.

The biographical details of Mr. Chan are as follows:

Mr. Chan, aged 46, is a fellow member of the Hong Kong Institute of Certified Public Accountants. He has more than 15 years of experience in corporate governance, compliance and company secretarial areas.

Having considered Mr. Chan's professional qualifications and experience, the Board is of the view that Mr. Chan possesses the relevant qualifications and experience under Rule 3.28 of the Listing Rules and is therefore capable of discharging the responsibilities of the Company Secretary.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Ng and Ms. Li for their valuable contribution and their work to the Company, and welcome Dr. Xu, Ms. Ding and Mr. Chan to their new appointments.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board further announces that the Company's principal place of business in Hong Kong will be changed to Unit 2405, 24/F., World Wide House, 19 Des Voeux Road Central, Central, Hong Kong with effect from July 31, 2026. The telephone number, facsimile number and website of the Company remain unchanged.

By order of the Board
Medtide Inc.
Dr. Xu Qi
Chairwoman and Chief Executive Officer

Hong Kong, July 31, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).